Print PRINT
X
Retinal Stabilizing Adjuncts

Retinal Stabilizing Adjuncts

Featured products

ISPAN* SF6 Intraocular Gas

ISPAN* SF6 Intraocular Gas
  • 8065797001 450 gm
  • 8065797002 125 gm
  • 8065797003 20 gm

ISPAN* C3F8 Intraocular Gas for the CONSTELLATION® Vision System

 
  • 8065797105 125 gm

ISPAN* C3F8 Intraocular Gas

ISPAN* C3F8 Intraocular Gas
  • 8065797101 450 gm
  • 8065797102 125 gm
  • 8065797103 20 gm

ISPAN* Tank Stand

ISPAN* Tank Stand
  • 8065797201

ISPAN* Tank Regulator

ISPAN* Tank Regulator
  • 8065797303
  • 450, 125, 20 gm

SF6 Return Box

SF6 Return Box
  • 8065797701

C3F8 Return Box

C3F8 Return Box
  • 8065797601
View Important Product Information for
ISPAN* Intraocular Gases +

ISPAN* Perfluoropropane (C3F8) Gas Brief Statement

Description: ISPAN* Perfluoropropane (C3F8) is a liquefied gas under pressure and is administered by injection into the vitreous cavity. It is Octafluoropropane (C3F8) from the Haloalkanes chemical family. The boiling point is -36.7°C (-34.1°F) and the vapor pressure at 20°C is 100 psig (pounds per square inch gauge). Perfluoropropane is clear and colorless with a faintly sweet odor. ISPAN* C3F8 purity: perfluoropropane (Octafluoropropane) 99.8% (minimum), air 1000 ppm (maximum) and perfluoropropene 10 ppm (maximum).

Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician.

Indications: ISPAN* Perfluoropropane (C3F8) is a surgical aid for use in the treatment of uncomplicated retinal detachment by pneumatic retinopexy. It is used in the form of an intravitreal injection for selected retinal breaks and to aid in resorption of subretinal fluid. Associated measures used include transconjunctival and transcleral cryotherapy and laser photocoagulation.

Contraindications: Proliferative vitreoretinopathy (PVR) greater than Stage C, then mental or physical inability to maintain the therapeutic position for 5 postoperative days, severe glaucoma with more than a minimum of field loss and a cup to disc ratio equal to or greater than 0.6; uveitis; severe peripheral retinal degeneration; and high altitude travel, include but not limited to airline travel.

Warnings: Use of Nitrous Oxide (N2O) must be stopped at least 10 minutes before gas injection to ensure an adequate postoperative bubble is achieved. Do not administer Nitrous Oxide (N2O) if a gas bubble is present.

Do not use the ISPAN* gas if the cylinder pressure is below 50 psi as the expansion performance of the gas may change resulting in elevated intraocular pressure.

Precautions: Caution should be used in eyes with angle recession, pigment dispersion syndrome, significant anterior synechiae, traumatized eyes and eyes with significant vitreous hemorrhage obscuring an adequate view of the peripheral retina.

Attention: Reference the Physician Labeling/Directions for Use for a complete listing of adverse reactions, warnings and precautions.

Sulfur Hexafluoride (SF6) Gas Brief Statement

Description: ISPAN* Sulfur Hexafluoride (SF6) is a liquefied gas under pressure and is administered by injection into the vitreous cavity. It is a colorless, odorless, non-toxic, nonflammable gas. The boiling point is -63.9°C (-83°F) and the vapor pressure at 20°C is 320 psig (pounds per square inch gauge). ISPAN* SF6 purity: sulfur hexafluoride 99.99% (minimum), air 100 ppm (maximum) carbon tetrafluoride 100 ppm (maximum) and hydrogen fluoride 0.3 ppm (maximum).

Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician.

Indications: ISPAN* Sulfur Hexafluoride (SF6) gas is a surgical aid for use in the treatment of uncomplicated retinal detachment by pneumatic retinopexy. It is used in the form of an intravitreal injection of selected retinal breaks and to aid in resorption of subretinal fluid. Associated measures used include transconjunctival and transcleral cryotherapy and laser photocoagulation.

Contraindications: Proliferative vitreoretinopathy (PVR) greater than Stage C, then mental or physical inability to maintain the therapeutic position for 5 postoperative days, severe glaucoma with more than a minimum of field loss and a cup to disc ratio equal to or greater than 0.6; uveitis; severe peripheral retinal degeneration; and high altitude travel, include but not limited to airline travel.

Warnings: Use of Nitrous Oxide (N2O) must be stopped at least 10 minutes before gas injection to ensure an adequate postoperative bubble is achieved. Do not administer Nitrous Oxide (N2O) if a gas bubble is present.

Do not use the ISPAN* gas if the cylinder pressure is below 50 psi as the expansion performance of the gas may change resulting in elevated intraocular pressure.

Precautions: Caution should be used in eyes with angle recession, pigment dispersion syndrome, significant anterior synechiae, traumatized eyes and eyes with significant vitreous hemorrhage obscuring an adequate view of the peripheral retina.

Attention: Reference the Physician Labeling/Directions for Use for a complete listing of adverse reactions, warnings and precautions.

*Trademarks are property of their respective owners.

ISPAN* Perfluoropropane (C3F8) Gas Brief Statement

Description: ISPAN* Perfluoropropane (C3F8) is a liquefied gas under pressure and is administered by injection into the vitreous cavity. It is Octafluoropropane (C3F8) from the Haloalkanes chemical family. The boiling point is -36.7°C (-34.1°F) and the vapor pressure at 20°C is 100 psig (pounds per square inch gauge). Perfluoropropane is clear and colorless with a faintly sweet odor. ISPAN* C3F8 purity: perfluoropropane (Octafluoropropane) 99.8% (minimum), air 1000 ppm (maximum) and perfluoropropene 10 ppm (maximum).

Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician.

Indications: ISPAN* Perfluoropropane (C3F8) is a surgical aid for use in the treatment of uncomplicated retinal detachment by pneumatic retinopexy. It is used in the form of an intravitreal injection for selected retinal breaks and to aid in resorption of subretinal fluid. Associated measures used include transconjunctival and transcleral cryotherapy and laser photocoagulation.

Contraindications: Proliferative vitreoretinopathy (PVR) greater than Stage C, then mental or physical inability to maintain the therapeutic position for 5 postoperative days, severe glaucoma with more than a minimum of field loss and a cup to disc ratio equal to or greater than 0.6; uveitis; severe peripheral retinal degeneration; and high altitude travel, include but not limited to airline travel.

Warnings: Use of Nitrous Oxide (N2O) must be stopped at least 10 minutes before gas injection to ensure an adequate postoperative bubble is achieved. Do not administer Nitrous Oxide (N2O) if a gas bubble is present.

Do not use the ISPAN* gas if the cylinder pressure is below 50 psi as the expansion performance of the gas may change resulting in elevated intraocular pressure.

Precautions: Caution should be used in eyes with angle recession, pigment dispersion syndrome, significant anterior synechiae, traumatized eyes and eyes with significant vitreous hemorrhage obscuring an adequate view of the peripheral retina.

Attention: Reference the Physician Labeling/Directions for Use for a complete listing of adverse reactions, warnings and precautions.

Sulfur Hexafluoride (SF6) Gas Brief Statement

Description: ISPAN* Sulfur Hexafluoride (SF6) is a liquefied gas under pressure and is administered by injection into the vitreous cavity. It is a colorless, odorless, non-toxic, nonflammable gas. The boiling point is -63.9°C (-83°F) and the vapor pressure at 20°C is 320 psig (pounds per square inch gauge). ISPAN* SF6 purity: sulfur hexafluoride 99.99% (minimum), air 100 ppm (maximum) carbon tetrafluoride 100 ppm (maximum) and hydrogen fluoride 0.3 ppm (maximum).

Caution: Federal (USA) law restricts this device to sale by, or on the order of, a physician.

Indications: ISPAN* Sulfur Hexafluoride (SF6) gas is a surgical aid for use in the treatment of uncomplicated retinal detachment by pneumatic retinopexy. It is used in the form of an intravitreal injection of selected retinal breaks and to aid in resorption of subretinal fluid. Associated measures used include transconjunctival and transcleral cryotherapy and laser photocoagulation.

Contraindications: Proliferative vitreoretinopathy (PVR) greater than Stage C, then mental or physical inability to maintain the therapeutic position for 5 postoperative days, severe glaucoma with more than a minimum of field loss and a cup to disc ratio equal to or greater than 0.6; uveitis; severe peripheral retinal degeneration; and high altitude travel, include but not limited to airline travel.

Warnings: Use of Nitrous Oxide (N2O) must be stopped at least 10 minutes before gas injection to ensure an adequate postoperative bubble is achieved. Do not administer Nitrous Oxide (N2O) if a gas bubble is present.

Do not use the ISPAN* gas if the cylinder pressure is below 50 psi as the expansion performance of the gas may change resulting in elevated intraocular pressure.

Precautions: Caution should be used in eyes with angle recession, pigment dispersion syndrome, significant anterior synechiae, traumatized eyes and eyes with significant vitreous hemorrhage obscuring an adequate view of the peripheral retina.

Attention: Reference the Physician Labeling/Directions for Use for a complete listing of adverse reactions, warnings and precautions.

*Trademarks are property of their respective owners.